サンプル依頼リスト カート
  • English
表紙：世界の母性保健市場-2023年～2030年
市場調査レポート
商品コード
1352125

世界の母性保健市場-2023年～2030年

Global Maternal Health Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
世界の母性保健市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の母性保健市場は2022年に141億米ドルに達し、2023～2030年の予測期間中にCAGR 8.5％で成長し、2030年には283億米ドルに達すると予測されています。

母性保健市場は、意識と教育の向上、妊産婦年齢の上昇、政府の取り組み、ヘルスケアインフラの成長、妊産婦のメンタルヘルスに対する認識といった要因によって牽引されています。

定期的な検診、スクリーニング、検査は、妊娠中の適切な出産前ケアの一環です。母体と成長する胎児の健康は、潜在的な問題の早期発見と治療によって確保されます。母体と胎児の健康は、バランスのとれた良い食事をとることにかかっています。胎児の成長と発育は、必要な栄養素の十分な摂取によって支えられ、母体の健康も守られます。

ダイナミクス

主要企業間の協力関係の強化が世界の母性保健市場の成長を牽引

2023年5月、CORONA Remedies Private Limited（CORONA）は、母性保健と泌尿器科領域で特徴的かつ画期的な製品を商品化するため、Ferring Pharmaceuticals Pvt. Ltd.（フェリング）と契約を締結しました。フェリングは、スイスに本社を置く世界のバイオ医薬品企業であるフェリング・ファーマシューティカルズ社の子会社です。

CORONAとFerringの提携により、インド全土の患者に対し、泌尿器科および母性保健分野で満たされていない治療要件を満たす最先端の製品（一部は国際ブランドの製品）を提供することになります。両社は、研究主導型の専門バイオ医薬品グループであるフェリングと協力し、インドの患者に一流の医薬品を提供できることを歓迎しています。

母性保健への資金提供の増加が世界の母性保健市場の成長を後押し

2023年1月、タミル・ナードゥ州ヴェロールにあるキリスト教医科大学（CMC）は、米国国際開発庁（USAID）の支援により、先進的なシミュレーション・ラボ・センターを持つことになっています。このラボは、心肺蘇生法、基本的および高度な看護技術、母性保健と新生児の緊急事態に対処するための最新技術など、妊産婦と新生児ケアの医療専門家の訓練に使用されます。

USAIDのAmerican Schools and Hospitals Abroad（ASHA）プログラムは、Advanced Simulation Lab Centerに100万米ドル（米ドル）の助成金を提供します。ASHAは、米国人とインド人の間に友好的で互恵的な関係を築くために活動しています。患者の安全性、プロトコル、ディブリーフィング方法は学生の評価とフィードバックにとって極めて重要であるため、この施設ではこれらの分野で米国のベストプラクティスを採用しています。病院の新生児重症治療室や分娩室のための近代的な備品や設備も、この取り組みを通じてUSAIDから提供されたものです。

母性保健の課題が世界の母性保健市場の成長を妨げる

多くの地域で、特に十分なサービスを受けていない人々にとって、質の高い医療サービスへのアクセスに格差があり、それが母性保健の結果に悪影響を及ぼしています。出産前のケアが不十分であることは、適切な母性保健に関する知識や理解の不足に起因している可能性があり、妊娠・出産を通じて問題を引き起こす可能性があります。多くの女性、特に低所得者や保険未加入の人々にとって、出産前ケア、出産、産後ケアを含む質の高い母性保健サービスにかかる費用は法外です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要企業間の協力関係の高まり
    • 抑制要因
      • 母性保健に関する課題
    • 機会
      • 技術進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 治療法別

  • ホルモン
  • 栄養剤
  • 鎮痛剤
  • 抗感染症薬
  • その他

第10章 適応症別

  • 流産
  • 早産・出産
  • その他

第11章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • Johnson & Johnson
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Jiovio Healthcare
  • Pfizer Inc
  • GlaxoSmithKline Inc.
  • Merck & Co., Inc.
  • RAND Corporation
  • SYNAPSE Product Development
  • Siemens
  • Reckitt Benckiser Group Plc
  • Sanofi

第15章 付録

目次
Product Code: PH6866

Overview

The Global Maternal Health Market reached US$ 14.1 billion in 2022 and is expected to reach US$ 28.3 billion by 2030 growing with a CAGR of 8.5% during the forecast period 2023-2030.

The maternal health market is driven by factors such as increasing awareness and education, rising maternal age, government initiatives, growing healthcare infrastructure and awareness of maternal mental health.

Regular medical check-ups, screenings, and testing are part of proper prenatal care during pregnancy. The health of the mother and the growing fetus is ensured through early detection and treatment of any potential issues. The health of the mother and the unborn child depends on eating a good and balanced diet. The growth and development of the fetus are supported by an adequate intake of necessary nutrients, which also protects the mother's health.

Dynamics

The Increasing Collaboration Among Key Players is Driving the Global Maternal Health Market Growth

In May 2023, in order to commercialize distinctive and ground-breaking products in the areas of Maternal Health & Urology, CORONA Remedies Private Limited (CORONA) entered into an agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of global biopharmaceuticals company Ferring Pharmaceuticals with headquarters in Switzerland.

The partnership between CORONA and Ferring will provide patients all over India with cutting-edge products, some of which will be from international brands, to meet the unmet treatment requirements in urology and maternal health. They are thrilled to collaborate with Ferring, a research-driven, specialty biopharmaceutical group, to provide patients in India with top-notch medications.

The Increasing Funding for Maternal Health Boost The Global Maternal Health Market Growth

In January 2023, The Christian Medical College (CMC) in Vellore, Tamil Nadu, now has an advanced simulation lab center due to the U.S. Agency for International Development (USAID). The lab will be used to train medical professionals in maternal and neonatal care, including CPR, basic and advanced nursing techniques, and the newest technologies to address maternal health and newborn emergencies.

The American Schools and Hospitals Abroad (ASHA) program of USAID provides a $1 million (USD) grant to fund the Advanced Simulation Lab Center. ASHA works to create friendly and mutually beneficial relationships between Americans and Indians. Since patient safety, protocols, and debriefing methods are crucial for student evaluation and feedback, the institution adopts American best practices in these areas. Modern supplies and equipment for the hospital's neonatal critical care unit and labor and delivery rooms were also made possible by USAID through this effort.

Challenges with Maternal Health are Hampering the Global Maternal Health Market Growth

There are discrepancies in access to high-quality healthcare services in many areas, especially for underserved people, which has a negative impact on maternal health outcomes. Poor prenatal care can stem from a lack of knowledge and understanding about proper maternal health care, which could cause issues throughout pregnancy and childbirth. For many women, particularly in low-income or uninsured populations, the expense of high-quality maternal health services, including prenatal care, delivery, and postnatal care, can be prohibitive.

Segment Analysis

The global maternal health market is segmented based on treatment, indication, distribution channel, and region.

The Hormones Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The hormones segment accounted for the highest market stake accounting for approximately 45.4% of the maternal health market in 2022. Hormones and maternal health are tightly related during pregnancy and the postpartum period. The different physiological and mental changes that take place in a woman's body during pregnancy and after childbirth are significantly regulated by hormones.

For the mother's and the fetus's health to be maintained during pregnancy, specific hormones must be produced in greater quantities. The most notable hormones involved in pregnancy are progesterone, estrogen, human chorionic gonadotropin hormone (hCG), and human placental lactogen (hPL). A hormone called progesterone is essential for preserving the uterine lining and avoiding contractions. Progesterone supplements may occasionally be advised for women who have a history of recurrent miscarriages or who have a short cervix.

Geographical Penetration

North America Holds a Dominant Position in the Global Maternal Health Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. In October 2022, The Special Supplemental Nutrition Program for Women, Infants, and Children, or WIC, has undergone significant modernization and innovation, and the U.S. Department of Agriculture recognizes its accomplishment and promise. The American Rescue Plan Act of 2021 has provided funding for three significant awards totaling about $53 million, as part of the efforts.

Together, these investments will increase the number of eligible women and young children that WIC reaches, improve the level of care that they get throughout their involvement with the program, and assist to close long-standing gaps in maternal and child health.

Competitive Landscape

The major global players in the market include: Johnson & Johnson, Jiovio Healthcare, Pfizer Inc., GlaxoSmithKline Inc., Merck & Co., Inc., RAND Corporation, SYNAPSE Product Development, Siemens, Reckitt Benckiser Group Plc, Sanofi among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the maternal health market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. It may be challenging for expectant mothers to get adequate prenatal and postnatal care if healthcare facilities are damaged or destroyed as a result of the conflict. Conflict zones' hospitals and clinics may be overburdened or unable to deliver proper care.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the maternal health market to improve various aspects of data analysis. A pregnant woman's medical history, health information, and lifestyle choices can be analyzed by AI algorithms to identify potential risk factors and forecast difficulties during pregnancy. This enables medical practitioners to develop individualized care regimens and intervene early.

Pregnant women can remotely monitor their health due to wearable technology and mobile apps that are powered by AI. These gadgets can monitor fetal movements, contraction patterns, and other pertinent information, alerting medical professionals if any unsettling trends are found.

By Treatment

  • Hormones
  • Nutritives
  • Analgesics
  • Anti-Infectives
  • Others

By Indication

  • Miscarriage
  • Premature Labor and Birth
  • Others

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, MedArrive, the top mobile-integrated care management solution, announced a partnership with Ouma Health, a provider of whole maternity telehealth services, in order to provide complete maternal-fetal care to at-risk women on Medicaid. By including a crucial service into MedArrive's expanding ecosystem of specialized care providers that managed Medicaid health plans can utilize for members in their homes, the collaboration intends to improve the health of expectant mothers and their newborns, particularly those at high risk.

Why Purchase the Report?

  • To visualize the global maternal health market segmentation based on the treatment, indication, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of maternal health market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of critical products of all the major players.

The global maternal health market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising collaboration among key players
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with maternal health
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment
  • 9.2. Hormones*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nutritives
  • 9.4. Analgesics
  • 9.5. Anti-Infectives
  • 9.6. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Miscarriage*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Premature Labor and Birth
  • 10.4. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Johnson & Johnson*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Jiovio Healthcare
  • 14.3. Pfizer Inc
  • 14.4. GlaxoSmithKline Inc.
  • 14.5. Merck & Co., Inc.
  • 14.6. RAND Corporation
  • 14.7. SYNAPSE Product Development
  • 14.8. Siemens
  • 14.9. Reckitt Benckiser Group Plc
  • 14.10. Sanofi

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us